Your search for supplemental oxygen returned 66 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for supplemental oxygen returned 66 results

Sort Results:

Relevant Recent
Features

The Clinician’s Guide to In-Flight Emergencies

Physicians are frequently called upon to assist fellow passengers who are ill during flight. A recent article addresses the ethical and legal considerations for physicians who provide medical services to patients during commercial flights.
News

Azithromycin Delays Next Hospitalization in COPD

For patients with chronic obstructive pulmonary disease (COPD) hospitalized for a respiratory-related event, administration of azithromycin is associated with a prolonged time to next respiratory hospitalization.
Clinical Charts

Anaphylaxis Management

Anaphylaxis management for outpatients, inpatients, and patients at discharge.
APS 2011 Acute Pain

MoxDuo’s Respiratory Safety Profile vs. Morphine or Oxycodone Alone

The MoxDuo combination of morphine and oxycodone may have a superior respiratory safety profile to that of equianalgesic morphine equivalent doses (MED) of either morphine or oxycodone alone, according to results presented at the American Pain Society's 30th Annual Scientific Meeting.
News

Mycamine Approved for Invasive Candidiasis in Younger Patients

The Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for Mycamine (micafungin for injection; Astellas Pharma) for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
News

Storage Update for Orfadin Capsules

The FDA has approved the supplemental new drug applicationfor Orfadin (nitisinone capsules; Sobi) which allows for an extension of shelf life for the 20mg capsules from 24 months to 36 months.
News

Delzicol Gains Expanded Pediatric Use for UC

The FDA has approved a supplemental new drug application (sNDA) for Delzicol (mesalamine) Delayed-Release Capsules for the treatment of mildly to moderately active ulcerative colitis in patients ≥5 years of age.